

# Extended Hormone Therapy May Be of Benefit

BY BRUCE JANCIN

**SAN ANTONIO** — Women who were premenopausal at diagnosis of early-stage breast cancer and subsequently completed 5 years of adjuvant tamoxifen derived additional benefit from extended aromatase inhibitor therapy, according to a new secondary analysis of a landmark clinical trial.

Five years of extended aromatase inhibitor therapy led to significantly improved disease-free survival in the National Cancer Institute of Canada Clinical Trials Group MA 17 trial, even with a median 3-year and maximum 6-year delay between completion of the tamoxifen regimen and the start of letrozole, Dr. Paul E. Goss reported at the San Antonio Breast Cancer Symposium.

Previous results from MA 17 led to regulatory approval of 5 years of letrozole following 5 years of adjuvant tamoxifen in patients with early-stage breast cancer. However, since most trials of early adjuvant aromatase inhibitor therapy required participants to be postmenopausal at diagnosis of their breast cancer, up until now the common clinical practice in low-risk women with premenopausal breast cancer has been to give 5 years of tamoxifen and then stop.

The new MA 17 analysis found that extended aromatase inhibitor therapy is beneficial in women who are premenopausal at diagnosis and become postmenopausal before or during adjuvant tamoxifen therapy. Such patients actually derived greater benefit than did women who were postmenopausal at diagnosis, according to Dr. Goss, director of breast cancer research at Massachusetts General Hospital and professor of medicine at Harvard Medical School, Boston.

Indeed, breast cancer patients who are premenopausal at diagnosis but become postmenopausal before or during tamoxifen therapy should routinely be considered for 5 years of extended aromatase inhibitor therapy, he added.

The MA 17 trial included 889 women who were premenopausal and 4,277 who were postmenopausal at the time of their primary cancer diagnosis. There were nine recurrences in 424 premenopausal-at-diagnosis patients randomized to letrozole after tamoxifen, which translated to an absolute 10.1% advantage in 4-year disease-free survival over the premenopausal-at-diagnosis group assigned to placebo following tamoxifen (Hazard ratio = 0.25,  $P = .0001$ ).

In contrast, there were 83 recurrences among 2,157 postmenopausal women who got extended adjuvant therapy with letrozole, for an absolute 3.3% improvement over placebo in terms of 4-year disease-free survival ( $HR = 0.69, P = .0008$ ). Recurrence was 61% less likely in letrozole-treated women who were premenopausal at diagnosis of their primary breast cancer than in those who were postmenopausal at that time.

Particularly striking was the advantage conferred by extended aromatase inhibitor therapy in women with node-neg-

ative premenopausal breast cancer. Their 4-year disease-free survival was 100% compared to 88.5% in those on placebo, for an absolute 11.5% difference, which Dr. Goss called "remarkable."

The benefit of extended adjuvant therapy was similar in the 290 women with premenopausal breast cancer who didn't start adjuvant letrozole until a median of 3 and maximum of 6 years after they completed their tamoxifen regimen and

in those who started letrozole directly after tamoxifen. The 5-year disease-free survival in the delayed-start group with premenopausal breast cancer was an absolute 8.2% better than in 135 others who elected not to go on the aromatase inhibitor.

The same trends seen in disease-free survival were noted in terms of the end point of 4-year distant disease-free survival.

Women with premenopausal breast cancer tolerated letrozole well. They had

a 24% incidence of arthralgia compared to 16% with placebo, but only a 10% rate of vaginal bleeding vs. 16% with placebo. Letrozole-treated women with postmenopausal breast cancer had significantly higher rates of hot flashes than with placebo, by a margin of 55% to 50%, as well as arthralgia (25% vs. 21%), myalgia (15% vs. 12%), and hair loss (5% vs. 3%). Dr. Goss is on the speakers bureaus for Novartis, Wyeth, and GlaxoSmithKline. ■



## NEW FOR HYPERTENSION

# APPROVED & AVAILABLE

**TWYNSTA® (telmisartan/amlodipine) tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents.<sup>1</sup>**

**TWYNSTA may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.<sup>1</sup>**

### IMPORTANT SAFETY INFORMATION

#### **WARNING: AVOID USE IN PREGNANCY**

**When used in pregnancy, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, TWYNSTA® (telmisartan/amlodipine) tablets should be discontinued as soon as possible (See Warnings and Precautions).**

Correct any volume depletion or salt depletion before initiation of therapy. Observe for signs and symptoms of hypotension, in particular in patients with severe aortic stenosis.

In patients with heart failure, renal artery stenosis or severe renal impairment, care should be exercised with dosing of TWYNSTA. In patients with severe heart failure, decline in renal function and, rarely, acute renal failure and/or death has been associated with inhibiting the renin-angiotensin system.

TWYNSTA is not recommended as initial therapy in hepatically impaired patients.

Use of telmisartan with an ACE inhibitor is not recommended.

Uncommonly, increased frequency, duration, and/or severity of angina or acute myocardial infarction have developed in patients treated with calcium channel blockers, particularly patients with severe obstructive coronary artery disease.

**Please see Brief Summary of Prescribing Information on adjacent page.**

**Reference:** 1. Twynsta PI. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009.

**NEW**  
**TWYNSTA®**  
(telmisartan/amlodipine) tablets  
40/5 • 40/10 • 80/5 • 80/10 mg

